Spyglass Pharma Inc (SGP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2006 | 12-2005 | 12-2004 | 12-2003 | 12-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,143,000 | 269,000 | -947,000 | -92,000 | 1,974,000 |
| Depreciation Amortization | 568,000 | 486,000 | 453,000 | 417,000 | 372,000 |
| Accounts receivable | -241,000 | -209,000 | -7,000 | 603,000 | 7,000 |
| Other Working Capital | 407,000 | 101,000 | 674,000 | -317,000 | -516,000 |
| Other Operating Activity | 284,000 | 235,000 | -327,000 | -10,000 | 143,000 |
| Operating Cash Flow | $2,161,000 | $882,000 | $-154,000 | $601,000 | $1,980,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,449,000 | 33,000 | N/A | N/A | N/A |
| PPE Investments | -449,000 | -435,000 | -482,000 | -701,000 | -770,000 |
| Purchase Of Investment | N/A | N/A | -2,852,000 | -2,169,000 | -482,000 |
| Sale Of Investment | N/A | N/A | 2,588,000 | 2,063,000 | 303,000 |
| Other Investing Activity | -10,000 | -52,000 | 125,000 | 17,000 | -19,000 |
| Investing Cash Flow | $-2,908,000 | $-454,000 | $-621,000 | $-790,000 | $-968,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 900,000 | 546,000 | N/A | N/A |
| Debt Issued | N/A | N/A | N/A | 2,369,000 | N/A |
| Debt Repayment | N/A | N/A | -18,000 | N/A | N/A |
| Common Stock Issued | 83,000 | 60,000 | -34,000 | N/A | N/A |
| Dividend Paid | -412,000 | -410,000 | -354,000 | -830,000 | -983,000 |
| Other Financing Activity | -1,032,000 | -1,183,000 | 1,394,000 | -657,000 | 783,000 |
| Financing Cash Flow | $-1,361,000 | $-633,000 | $1,534,000 | $882,000 | $-200,000 |
| Exchange Rate Effect | 7,000 | -12,000 | 7,000 | 4,000 | -7,000 |
| Beginning Cash Position | 4,767,000 | 4,984,000 | 4,218,000 | 3,521,000 | 2,716,000 |
| End Cash Position | 2,666,000 | 4,767,000 | 4,984,000 | 4,218,000 | 3,521,000 |
| Net Cash Flow | $-2,101,000 | $-217,000 | $766,000 | $697,000 | $805,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,161,000 | 882,000 | -154,000 | 601,000 | 1,980,000 |
| Capital Expenditure | -458,000 | -478,000 | -489,000 | -711,000 | -776,000 |
| Free Cash Flow | 1,703,000 | 404,000 | -643,000 | -110,000 | 1,204,000 |